Literature DB >> 35927344

Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report.

Yujie Shi1, Jian Li2,3, Lu Zhang4,5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35927344     DOI: 10.1007/s00277-022-04926-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   4.030


× No keyword cloud information.
  5 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.

Authors:  Yujun Dong; Lu Zhang; Lin Nong; Lihong Wang; Zeyin Liang; Daobin Zhou; David C Fajgenbaum; Hanyun Ren; Jian Li
Journal:  Ann Hematol       Date:  2018-05-07       Impact factor: 3.673

3.  Acute Kidney Injury Caused by TAFRO Syndrome in a Chinese Patient: Efficacy of Long-Term Corticosteroids Combined with Bortezomib and Cyclophosphamide.

Authors:  Peng Xia; Lu Zhang; Menglian Zou; Tengyue Zhang; Ran Li; Xiaoxiao Shi; Jing Wang; Yan Qin; Xuemei Li; Jian Li; Limeng Chen
Journal:  Kidney Blood Press Res       Date:  2020-06-03       Impact factor: 2.687

4.  A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.

Authors:  Lu Zhang; Miao-Yan Zhang; Xin-Xin Cao; Dao-Bin Zhou; David C Fajgenbaum; Yu-Jun Dong; Jian Li
Journal:  Leuk Lymphoma       Date:  2022-01-31

5.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Authors:  Frits van Rhee; Peter Voorhees; Angela Dispenzieri; Alexander Fosså; Gordan Srkalovic; Makoto Ide; Nikhil Munshi; Stephen Schey; Matthew Streetly; Sheila K Pierson; Helen L Partridge; Sudipto Mukherjee; Dustin Shilling; Katie Stone; Amy Greenway; Jason Ruth; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Raj Jayanthan; Elaine S Jaffe; Heather Leitch; Naveen Pemmaraju; Amy Chadburn; Megan S Lim; Kojo S Elenitoba-Johnson; Vera Krymskaya; Aaron Goodman; Christian Hoffmann; Pier Luigi Zinzani; Simone Ferrero; Louis Terriou; Yasuharu Sato; David Simpson; Raymond Wong; Jean-Francois Rossi; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Eric Oksenhendler; David C Fajgenbaum
Journal:  Blood       Date:  2018-09-04       Impact factor: 25.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.